CUV 1.42% $13.90 clinuvel pharmaceuticals limited

News: CUV UPDATE 1-U.S. FDA approves Clinuvel Pharma's rare genetic disorder treatment, page-120

  1. 578 Posts.
    lightbulb Created with Sketch. 84
    Massive, massive food for thought for any CUV shorters out there. Capital Research and Management has just (over the last few months) added 1.1m shares to their holding. According to Morningstar, this now makes them the biggest active institutional holder in CUV by far, above even the index fund shares held by Vanguard.

    https://www.morningstar.com/stocks/xber/ur9/ownership

    Capital is a deep research driven long term high conviction holder. They are a very serious, very well respected investment house, truly one of the best around. 941,000 shares are now in their 5 star rated Smallcap World A fund. It's a bit obvious to say, but if Capital did not believe CUV shares had a very attractive outlook, they'd steer well clear.

    Being a CUV holder has long felt a little odd due to the fact that institutions do not feature high up the list of holders. To have these guys jump to the top of the institutional holders list is a real validation of the strategy, operations, outlook, and management of CUV.
    Last edited by Frogster: 21/04/20
 
watchlist Created with Sketch. Add CUV (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.